Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press30910.17650/1726-9776-2012-8-3-12-17LECTUREЛЕКЦИЯMAINTENANCE INTRAVESICULAR THERAPY WITH BCG VACCINE AS A STANDARD FOR THE PREVENTION AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN MODERATE AND HIGH RISK GROUPSПОДДЕРЖИВАЮЩАЯ ВНУТРИПУЗЫРНАЯ ТЕРАПИЯ ВАКЦИНОЙ БЦЖ КАК СТАНДАРТ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ ПРОМЕЖУТОЧНОЙ И ВЫСОКОЙ ГРУПП РИСКАAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruGolovashchenkoM. P.ГоловащенкоМ. П.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Oncology Research InstituteМНИОИ им. П.А. Герцена300920128312170508201405082014https://oncourology.abvpress.ru/oncur/article/view/309

Notwithstanding the fact that BCG vaccine therapy is considered to be the most effective method to treat and prevent non-muscle invasive bladder cancer recurrences, maintenance therapy is performed insufficiently often. Whether long-term courses of intravesicular BCG installations are needed to obtain optimal results remains unsolved so far.

Несмотря на то, что терапия вакциной БЦЖ считается наиболее эффективным методом лечения и профилактики рецидивов немышечно-инвазивного рака мочевого пузыря, поддерживающий режим терапии применяется недостаточно часто. До сих пор остается нерешенным вопрос: требуется ли проведение пролонгированных курсов внутрипузырных инстилляций БЦЖ с целью получения оптимальных результатов?

non-muscle invasive bladder cancerBCGmaintenance therapyнемышечно-инвазивный рак мочевого пузыряБЦЖподдерживающая терапия1. Lamm D.L., Blumenstein B.A., Crissman J.D. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124−9.Lamm D.L., Blumenstein B.A., Crissman J.D. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124−9.2. Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964−70.Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964−70.3. Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90−5.Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal metaanalysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90−5.4. Böhle A., Bock P.R. Intravesical bacilli Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004;63:682−6.Böhle A., Bock P.R. Intravesical bacilli Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004;63:682−6.5. Sylvester R.J., van der Meijden A.P., Witjes J.A. et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86−91.Sylvester R.J., van der Meijden A.P., Witjes J.A. et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86−91.6. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A metaanalysis of randomized trials. Urology 2006;67:1216−23.Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A metaanalysis of randomized trials. Urology 2006;67:1216−23.7. Malmström P.U., Sylvester R.J., Crawford D.E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247−56.Malmström P.U., Sylvester R.J., Crawford D.E. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247−56.8. Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766−73.Sylvester R.J., Brausi M.A., Kirkels W.J. et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766−73.9. Hinotsu S., Akaza H., Naito S. et al. Maintenance therapy with bacillus Calmette-Guerin (BCG) Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive transitional cell carcinoma of the bladder. BJU Int 2011;108(2):187−95.Hinotsu S., Akaza H., Naito S. et al. Maintenance therapy with bacillus Calmette-Guerin (BCG) Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive transitional cell carcinoma of the bladder. BJU Int 2011;108(2):187−95.10. Lamm D., Persad R., Colombel M., Brausi M. Maintenance Bacillus Calmette-Guerin: The standard of care for the prophylaxis and management of intermediateand high-risk non-muscle-invasive bladder cancer. Eur Urol Suppl 2010;9:715−34.Lamm D., Persad R., Colombel M., Brausi M. Maintenance Bacillus Calmette-Guerin: The standard of care for the prophylaxis and management of intermediateand high-risk non-muscle-invasive bladder cancer. Eur Urol Suppl 2010;9:715−34.11. Taniguchi K., Koga S., Nishikido M. et al. Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol 1999;115:131−5.Taniguchi K., Koga S., Nishikido M. et al. Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol 1999;115:131−5.12. Chen F., Zhang G., Iwamoto Y., See W.A. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol 2005;5:8.Chen F., Zhang G., Iwamoto Y., See W.A. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol 2005;5:8.13. O’Donnell M.A., DeWolf W.C. BCG immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin North Amer 1995;4:189−202.O’Donnell M.A., DeWolf W.C. BCG immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin North Amer 1995;4:189−202.14. Prescott S., James K., Hargreave T.B. et al. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636−42.Prescott S., James K., Hargreave T.B. et al. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636−42.15. Cookson M.S., Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62−7.Cookson M.S., Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62−7.16. Reichert D.F., Lamm D.L. Long term protection in bladder cancer following intralesional immunotherapy. J Urol 1984; 132:570−3.Reichert D.F., Lamm D.L. Long term protection in bladder cancer following intralesional immunotherapy. J Urol 1984; 132:570−3.17. Shelley M.D., Mason M.D., Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010;36:195−205.Shelley M.D., Mason M.D., Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev 2010;36:195−205.18. Bladder cancer: guideline for the management of non-muscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelinesand-quality-care/clinical-guidelines.cfm?sub=bc&CFID=673377&CFTOKEN=95927192&jsessionid=843082c98dcd9c03ed6c6863583e7735217f.Bladder cancer: guideline for the management of non-muscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelinesand-quality-care/clinical-guidelines.cfm?sub=bc&CFID=673377&CFTOKEN=95927192&jsessionid=843082c98dcd9c03ed6c6863583e7735217f.19. Babjuk M., Oosterlinck W., Sylvester R. et al. Guidelines on Ta, T1(non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/gls/ pdf/TaT1%20(nonmuscle%20invasive)%20bladder%20cancer%202010.pdf.Updated 2009.Babjuk M., Oosterlinck W., Sylvester R. et al. Guidelines on Ta, T1(non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/gls/ pdf/TaT1%20(nonmuscle%20invasive)%20bladder%20cancer%202010.pdf.Updated 2009.20. Lamm D., Colombel M., Persad R. et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008;7:651−66.Lamm D., Colombel M., Persad R. et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008;7:651−66.21. Soloway M.S., editor. International consultation on bladder tumours. Urology 2005;66 (Suppl 1):1−125.Soloway M.S., editor. International consultation on bladder tumours. Urology 2005;66 (Suppl 1):1−125.22. Martinez-Pineiro J.A., Flores N., Isorna S. et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671−80.Martinez-Pineiro J.A., Flores N., Isorna S. et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671−80.23. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E. et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174:1242−7.Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E. et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174:1242−7.24. Lamm D., Böhle A., Palou J. et al. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur Urol 2010; 57:p7−9.Lamm D., Böhle A., Palou J. et al. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur Urol 2010; 57:p7−9.25. Huncharek M., Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: meta-analytic reevaluation. Am J Clin Oncol 2003;26:402−7.Huncharek M., Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: meta-analytic reevaluation. Am J Clin Oncol 2003;26:402−7.26. Huncharek M., Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004;27:522−8.Huncharek M., Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 2004;27:522−8.27. Järvinen R., Kaasinen E., Sankila A. et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent Ta, T1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009; 56(2):260−5.Järvinen R., Kaasinen E., Sankila A. et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent Ta, T1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009; 56(2):260−5.28. Witjes J.A., Palou J., Soloway M. et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur Urol Suppl 2008;7:667−74.Witjes J.A., Palou J., Soloway M. et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur Urol Suppl 2008;7:667−74.29. Böhle A., Balck F., von Wietersheim J., Jocham D. The quality of life during intravesical bacillus Calmette-Guérin therapy. J Urol 1996;155:1221−6.Böhle A., Balck F., von Wietersheim J., Jocham D. The quality of life during intravesical bacillus Calmette-Guérin therapy. J Urol 1996;155:1221−6.30. Lundholm C., Norlen B.J., Ekman P. et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996;156:372−6.Lundholm C., Norlen B.J., Ekman P. et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996;156:372−6.31. Krege S., Giani G., Meyer R. et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating Clinics. J Urol 1996;156:962−6.Krege S., Giani G., Meyer R. et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating Clinics. J Urol 1996;156:962−6.32. Lamm D.L. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992;19:565−72.Lamm D.L. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992;19:565−72.33. Falkensammer C., Gozzi C., Hager M. et al. Late occurrence of bilateral tuberculouslike epididymo-orchitis after intravescical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology 2005;65:175.Falkensammer C., Gozzi C., Hager M. et al. Late occurrence of bilateral tuberculouslike epididymo-orchitis after intravescical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology 2005;65:175.34. Steg A., Leleu C., Debre B. et al. Systemic bacillus Calmette-Guérin infection: ‘BCGitis’ in patients treated by intravescical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 1989;16:161−4.Steg A., Leleu C., Debre B. et al. Systemic bacillus Calmette-Guérin infection: ‘BCGitis’ in patients treated by intravescical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 1989;16:161−4.35. Witjes J.A., Palou J., Soloway M. et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur Urol Suppl 2008;7:667−74.Witjes J.A., Palou J., Soloway M. et al. Clinical practice recommendations for the prevention and management of intravesical therapy associated adverse events. Eur Urol Suppl 2008;7:667−74.36. Rischmann P. Improving compliance of BCG immunotherapy: practical approaches to managing side-effects. Eur Urol Suppl 2006;5:660−2.Rischmann P. Improving compliance of BCG immunotherapy: practical approaches to managing side-effects. Eur Urol Suppl 2006;5:660−2.37. Picard A., Champetier D., Perrin P. et al. Discontinuance of BCG instillation for non-muscle invasive bladder cancer: prognostic impact on recurrence. Poster presented at: European Association of Urology 25th Annual Congress; April 16−20, 2010; Barcelona, Spain.Picard A., Champetier D., Perrin P. et al. Discontinuance of BCG instillation for non-muscle invasive bladder cancer: prognostic impact on recurrence. Poster presented at: European Association of Urology 25th Annual Congress; April 16−20, 2010; Barcelona, Spain.38. Van der Meijden A.P.M., Sylvester R.J., Oosterlinck W. et al. for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429−34.Van der Meijden A.P.M., Sylvester R.J., Oosterlinck W. et al. for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429−34.39. Decobert M., LaRue H., Harel F. et al. Maintenance bacillus Calmette-Guérin in high-risk non-muscle invasive bladder cancer: how much is enough? Cancer 2008; 113:710−6.Decobert M., LaRue H., Harel F. et al. Maintenance bacillus Calmette-Guérin in high-risk non-muscle invasive bladder cancer: how much is enough? Cancer 2008; 113:710−6.40. Colombel M., Saint F., Chopin D. et al. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176:935−9.Colombel M., Saint F., Chopin D. et al. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176:935−9.41. Buckley R., Rischmann P., Colombel M. et al. Prophylactic ofloxacin to improve tolerance of BCG instillations: two-year results of a prospective double-blind placebocontrolled study in patients with bladder cancer [Abstract PD-11.12]. Poster presented at: Societe Internationale d’Urologie (SIU) 28th Congress; November 12−16, 2006; Cape Town, South Africa.Buckley R., Rischmann P., Colombel M. et al. Prophylactic ofloxacin to improve tolerance of BCG instillations: two-year results of a prospective double-blind placebocontrolled study in patients with bladder cancer [Abstract PD-11.12]. Poster presented at: Societe Internationale d’Urologie (SIU) 28th Congress; November 12−16, 2006; Cape Town, South Africa.42. Nieder A.M., Sved P.D., Stein J.P. et al. Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette-Guérin-induced bladder contractures. Urology 2005;65:909−12.Nieder A.M., Sved P.D., Stein J.P. et al. Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette-Guérin-induced bladder contractures. Urology 2005;65:909−12.